When and how should hyperprolactinemia be treated?;Quand et comment traiter une hyperprolactinémie?

Presse Medicale

Volumn 34, Issue 10, 2005, Pages 731-737

  Bachelot, Anne ^a   Courtillot, Carine ^a   Touraine, Philippe ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG; NEUROLEPTIC AGENT; QUINAGOLIDE;

AMENORRHEA; DISEASE EXACERBATION; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG WITHDRAWAL; GALACTORRHEA; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS ADENOMA; HYPOPHYSIS MACROADENOMA; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; MENSTRUATION DISORDER; NUCLEAR MAGNETIC RESONANCE IMAGING; PREGNANCY; PSYCHOSIS; RADIOIMMUNOASSAY; REVIEW; SEXUAL DYSFUNCTION; TUMOR VOLUME;

EID: 20944446123     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(05)84028-x     Document Type: Review

References (42)

1. Crosignani PG. Management of hyperprolactinemia in infertility. J Reprd Med 1999; 44: 1116-20.
2. Vanderpump MP, French JM, Appleton D, Tunbridge WM, Kendall-Taylor P. The prevalence of hyperprolactinaemia and association with markers of autoimmune thyroid disease in survivors of the Whickham Survey cohort. Clin Endocrinol (Oxf) 1998; 48: 39-44.
3. Schlechte JA. Clinical practice. Prolactinoma. N Engl J Med 2003; 349: 2035-41.
4. Miller KK, Klibanski A. Amenorrheic bone loss. J Clin Endocrinol Metab 1999; 84: 1775-83.
5. Clement-Lacroix P, Ormandy C, Lepescheux L, Ammann P, Damotte D, Goffin V et al. Osteoblasts are a new target for prolactin: analysis of bone formation in prolactin receptor knockout mice. Endocrinology 1999; 140: 96-10S.
6. Leslie H, Courtney CH, Bell PM, Hadden DR, McCance DR, Ellis PK et al. Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method. J Clin Endocrinol Metab 2001; 86: 2743-6.
7. Vallette-Kasic S, Morange-Ramos I, Selim A, Gunz G, Morange S, Enjalbert A et al. Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab 2002; 87: 581-8.
8. Touraine P, Plu-Bureau G, Beji C, Mauvais-Jarvis P, Kuttenn F. Long-term follow-up of 246 hyperprolactinemic patients. Acta Obstet Gynecol Scand 2000; 80: 162-8.
9. Naidich MJ, Russell EJ. Current approaches to imaging of the sellar region and pituitary. Endocrinol Metab Clin North Am 1999; 28: 45-79.
10. Molitch ME, Thorner MO, Wilson C. Management of prolactinomas. J Clin Endocrinol Metab 1997; 82: 996-1000.
11. Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A. The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 1989; 68: 412-18.
12. Sisam DA, Sheehan JP, Sheeler LR. The natural history of untreated microprolactinomas. Fertil Steril 1987; 48: 67-71.
13. Morange I, Barlier A, Pellegrini I, Brue T, Enjalbert A, Jaquet P. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy. Eur J Endocrinol 1996; 135: 413-20.
14. Schultz PN, Ginsberg L, McCutcheon IE, Samaan N, Leavens M, Gagel RF. Quinagolide in the management of prolactinoma. Pituitary 2000; 3: 239-49.
15. Colao A, Di Sarno A, Landi ML, Ferone D, Di Renzo G, Merola B et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 1997; 82: 876-83.
16. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline comparative study group. N Engl J Med 1994; 331: 904-9.
17. Verfielst J, Abs R, Marter D, van den Bruel A, Vandeweghe M, Velkeniers B et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999; 84: 2518-22.
18. Losa M, Mortini P, Barzaghi R, Gioia L, Giovanelli M. Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J Clin Endocrinol Metab 2002; 87: 3180-6.
19. De Leo V, Lanzetta D, Vanni AL, D'Antona D, Severi FM. Low oestrogen oral contraceptives and the hypothalamo-pituitary axis. Contraception 1991; 44: 155-61.
20. Corenblum B, Donovan L. The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil Steril 1993; 59: 671-3.
21. Testa G, Vegetti W, Motta T, Alagna F, Bianchedi D, Carlucci C et al. Two-year treatment with oral contraceptives in hyperprolactinemic patients. Contraception 1998; 58: 69-73.
22. Wang DY, De Stavola BL, Bulbrook RD, Allen DS, Kwa HG, Fentiman IS et al. Relationship of blood prolactin levels and the risk of subsequent breast cancer. Int J Epidemiol 1992; 21: 214-21.
23. Hankinson SE, Willett WC, Michaud DS Manson JE, Colditz GA, Longcope C et al. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999; 91: 629-34.
24. Tworoger SS, Eliassen AH, Rosner B, Sluss P, Hankinson SE. Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res 2004; 64: 6814-19.
25. Biller BM, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996; 81: 2338-43.
26. Ferrari CI, Abs R, Bevan JS, Brabant G, Ciccarelli E, Motta T et al. Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol 1997; 46: 409-13.
27. Colao A, Vitale G, Di Sarno A, Spiezia S, Guerra E, Ciccarelli A, Lombardi G. Prolactin and prostate hypertrophy: a pilot observational, prospective, case-control study in men with prolactinoma. J Clin Endocrinol Metab 2004; 89: 2770-5.
28. Molitch ME, Elton RL, Blackwell RE Caldwell B, Chang RJ, Jaffe R et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 1985; 60: 698-705.
29. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 2003; 349: 2023-33.
30. Van't Verlaat JW, Croughs RJ. Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size. Clin Endocrinol 1991; 34: 175-8.
31. Gen M, Uozumi T, Ohta M, Ito A, Kajiwara H, Mori S. Necrotic changes in prolactinomas after long term administration of bromocriptine. J Clin Endocrinol Metab 1984; 59: 463-70.
32. Bronstein MD, Salgado LR, de Castro Musolino NR. Medical management of pituitary adenomas: the special case of management of the pregnant woman. Pituitary 2002; 5: 99-107.
33. Touraine P, Deneux C, Plu-Bureau G, Mauvais-Jarvis P, Kuttenn F. Hormonal replacement therapy in menopausal women with a history of hyperprolactinemia. J Endocrinol Invest 1998; 21: 732-6.
34. Karunakaran S, Page RC, Wass JA. The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin Endocrinol 2001; 54: 295-300.
35. Krupp P, Monka C. Bromocriptine in pregnancy: safety aspects. Klin Wochenschr 1987; 65: 823-7.
36. Robert E, Musatti L, Piscitelli G, Ferrari CI. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 1996; 10: 333-7.
37. Molitch ME. Pituitary tumors and pregnancy. Growth Hormone and IGF Research 2003; 13: 538-44.
38. Molitch ME. Medical management of prolactin secreting pituitary adenomas. Pituitary 2002; 5: 55-65
39. David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 2000; 22: 1085-96.
40. Smith S. Neuroleptic-associated hyperprolactinemia. Can it be treated with bromocriptine? J Reprod Med 1992; 37: 737-40.
41. Tollin SR. Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. J Endocrinol Invest 2000; 23: 765-70.
42. Cavallaro R, Cocchi F, Angelone SM, Lattuada E, Smeraldi E. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry 2004; 65: 187-90.